Processa Pharmaceuticals Inc (NASDAQ: PCSA) on Friday, plunged -4.31% from the previous trading day, before settling in for the closing price of $0.26. Within the past 52 weeks, PCSA’s price has moved between $0.23 and $3.10.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 75.19%. With a float of $4.67 million, this company’s outstanding shares have now reached $5.27 million.
In an organization with 10 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Processa Pharmaceuticals Inc (PCSA) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Processa Pharmaceuticals Inc is 11.36%, while institutional ownership is 1.88%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.65 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.65% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
Processa Pharmaceuticals Inc (PCSA) is currently performing well based on its current performance indicators. A quick ratio of 1.22 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.89, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.61 million. That was better than the volume of 1.13 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.04%. Additionally, its Average True Range was 0.06.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 2.24%, which indicates a significant decrease from 10.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 181.14% in the past 14 days, which was higher than the 109.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4770, while its 200-day Moving Average is $1.0882. However, in the short run, Processa Pharmaceuticals Inc’s stock first resistance to watch stands at $0.2614. Second resistance stands at $0.2739. The third major resistance level sits at $0.2946. If the price goes on to break the first support level at $0.2282, it is likely to go to the next support level at $0.2075. Assuming the price breaks the second support level, the third support level stands at $0.1950.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats
Market capitalization of the company is 1.31 million based on 5,269K outstanding shares. Right now, sales total 0 K and income totals -11,850 K. The company made 0 K in profit during its latest quarter, and -2,730 K in sales during its previous quarter.
